<![CDATA[Chugai Pharmaceutical: News Releases]]> https://www.chugai-pharm.co.jp/english/index.html en-us Thu, 09 Apr 2026 15:30:00 +0900 <![CDATA[Announcement of Termination of Co-Promotion of Rituxan® in Japan (Anti-CD20 Monoclonal Antibody)]]> https://www.chugai-pharm.co.jp/english/news/detail/20260409153000_1239.html Thu, 09 Apr 2026 15:30:00 +0900 https://www.chugai-pharm.co.jp/english/news/detail/20260409153000_1239.html <![CDATA[Research Results on Immune Thrombocytopenia from a Joint Study with Osaka University’s IFReC Published in Blood]]> https://www.chugai-pharm.co.jp/english/news/detail/20260406153000_1240.html Mon, 06 Apr 2026 15:30:00 +0900 https://www.chugai-pharm.co.jp/english/news/detail/20260406153000_1240.html <![CDATA[Lilly’s Announcement Regarding Oral GLP-1 Foundayo™ (Orforglipron)]]> https://www.chugai-pharm.co.jp/english/news/detail/20260402083000_1238.html Thu, 02 Apr 2026 08:30:00 +0900 https://www.chugai-pharm.co.jp/english/news/detail/20260402083000_1238.html <![CDATA[Position and Policy Regarding Reduction of the Investment Unit]]> https://www.chugai-pharm.co.jp/english/news/detail/20260326170000_1237.html Thu, 26 Mar 2026 17:00:00 +0900 https://www.chugai-pharm.co.jp/english/news/detail/20260326170000_1237.html <![CDATA[Chugai Obtains Regulatory Approval for Lunsumio and Polivy Combination Therapy for Additional Indication of Relapsed or Refractory Large B-cell Lymphoma]]> https://www.chugai-pharm.co.jp/english/news/detail/20260323153000_1234.html Mon, 23 Mar 2026 15:30:00 +0900 https://www.chugai-pharm.co.jp/english/news/detail/20260323153000_1234.html <![CDATA[Notice Regarding Discontinuation of Development of GYM329 (Emugrobart) in Spinal Muscular Atrophy (SMA) and Facioscapulohumeral Muscular Dystrophy (FSHD) ]]> https://www.chugai-pharm.co.jp/english/news/detail/20260323083000_1236.html Mon, 23 Mar 2026 08:30:00 +0900 https://www.chugai-pharm.co.jp/english/news/detail/20260323083000_1236.html <![CDATA[Chugai Selected as a “Nadeshiko Brand” for FY2025]]> https://www.chugai-pharm.co.jp/english/news/detail/20260319153000_1233.html Thu, 19 Mar 2026 15:30:00 +0900 https://www.chugai-pharm.co.jp/english/news/detail/20260319153000_1233.html <![CDATA[Chugai Files for the Medical Device Component of the Port Delivery Platform with ranibizumab in Japan ]]> https://www.chugai-pharm.co.jp/english/news/detail/20260319163000_1235.html Thu, 19 Mar 2026 16:30:00 +0900 https://www.chugai-pharm.co.jp/english/news/detail/20260319163000_1235.html <![CDATA[Roche’s Announcement Regarding giredestrant (Announcement of Phase III persevERA Study Results)]]> https://www.chugai-pharm.co.jp/english/news/detail/20260310160000_1232.html Tue, 10 Mar 2026 16:00:00 +0900 https://www.chugai-pharm.co.jp/english/news/detail/20260310160000_1232.html